Immune Shift Between Eczematous Eruption and Psoriasiform Lesions

LI Yan,LI Ming,LI Linfeng

2023-01-01

Abstract:In treating the imbalance of the Th1/Th17 to Th2 response in psoriasis（PsO） or atopic dermatitis（AD） with biologics, the resulting shift in cytokine levels may paradoxically favor the opposing cutaneous disease.Patients with PsO develop eczematous reactions and patients with AD developed psoriasiform lesions.Eczematous skin eruptions have been observed during the treatments of many biologics, such as infliximab, etanercept, adalimumab, secukinumab, ixekizumab, ustekinumab, and guselkumab, while psoriasiform lesions have been observed during the treatments of dupilumab and upadacitinib.Patients with PsO who have a personal or family history of atopy, and patients with AD who have a personal or family history of PsO should be informed of adverse effects of immune drift.Skin histopathology is the gold standard for diagnosis.Topical corticosteroids can be used to treat mild lesions.If topical corticosteroids are not responsive, or the severity of skin lesions is moderate to severe, the prior treatment should be discontinued and the effective therapies for both diseases should be selected, such as phototherapy, cyclosporine, methotrexate, and mycophenolate.